## 14. Analysis of actual graft survival

Actual graft survival

In this analysis, graft failure and death with a functioning graft occurring after the 90th day of engraftment were counted as endpoints. Actual graft survival after twelve years was 56% in the statin group and 45% in the non-statin group (unadjusted p-value: 0.007). In the univariate analysis, statin treatment was associated with improved actual graft survival compared to untreated patients (HR 0.77, 95% CI 0.63-0.93, p-value 0.006) (see Figure), which was confirmed in the multivariable model (HR 0.68, 95% CI 0.55-0.84, p-value <0.001) (see Table), as well as by MSM analysis (HR 0.73, 95% CI 0.58-0.92, p-value 0.007) . There was no interaction between statin treatment and any of the covariates of the multivariable model.

Kaplan-Meier curves of actual graft survival (endpoints: graft failure and death with functioning graft) according to statin use treated as time-dependent variable. Figures on the bottom indicate patients at risk at different times of follow-up.

Patients at risk, Statin :

| 302 | 377 | 313 | 241 | 178 | 108 | 65 |

Patients at risk, NoStatin :

| 1739 | 1163 | 863 | 567 | 337 | 197 | 97 |